Table 1.
microRNAs experimentally validated to alter chemosensitivity of lung cancers
| Drug | MiRNAs Affecting Response to Drug |
Sensitivity Change When MiRNA Expressed |
References |
|---|---|---|---|
| TRAIL | miR-212,miR-130a | Increase | [57, 149] |
| miR-221/222 | Decrease | [52] | |
| Cisplatin | miR-181a, miR-181b | Increase | [100, 271-276] |
| miR-497, miR-451, miR-138, miR-200c miR-150 miR-134/379/495 miR-630, miR-106 |
Decrease | [67, 272] | |
| Doxorubicin | miR-1 | ||
| miR-134/379/495 | Increase | [132, 273] | |
| Docetaxel | miR-200b,miR-100 | Increase | [277, 278] |
| Cetuximab | miR-200c | Increase | [100] |
| Etoposide | miR-134/379/495 | Increase | [273] |
| MEK inhibitor | |||
| AZD6244 | miR-17 | Decrease | [279] |
| EGFR-TKI | |||
| AG1478 | miR-21 | Decrease | [36] |
| Vincristin | miR-181b, miR-497 | Increase | [275, 276] |
| DMC | miR-106, miR-150 | Decrease | [67] |
| Gefitinib | miR-221/222, miR-30b/c | Decrease | [58] |
| miR-21, miR-29a/c miR-100 miR-103, miR-203 |
Increase | [58] |
DMC, Demethylcantharidin.